In a previous study conducted during the era when ASS was classified within either DM or PM, researchers observed that anti-Ro-52 antibodies were linked to a 2.8-fold increased risk of pulmonary complications in dermatomyositis, while anti-Jo-1 antibodies were associated with a 3.9-fold higher risk of pulmonary disorders in polymyositis [20]. Here, TRIM21 is linked to lung disorder.